Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 23 10:47AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.50 Insider Own23.24% Shs Outstand2.47M Perf Week10.17%
Market Cap8.81M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.08M Perf Month20.82%
Income-15.60M PEG- EPS next Q- Inst Own38.63% Short Float0.75% Perf Quarter4.84%
Sales0.00M P/S- EPS this Y- Inst Trans21.81% Short Ratio2.87 Perf Half Y-12.63%
Book/sh3.97 P/B0.82 EPS next Y- ROA-116.78% Short Interest0.02M Perf Year-26.14%
Cash/sh2.10 P/C1.55 EPS next 5Y- ROE-192.45% 52W Range1.75 - 5.25 Perf YTD-2.99%
Dividend Est.- P/FCF- EPS past 5Y36.06% ROI-157.24% 52W High-38.10% Beta1.94
Dividend TTM- Quick Ratio4.17 Sales past 5Y-33.97% Gross Margin- 52W Low85.70% ATR (14)0.49
Dividend Ex-Date- Current Ratio4.17 EPS Y/Y TTM62.87% Oper. Margin0.00% RSI (14)56.79 Volatility27.13% 21.11%
Employees1 Debt/Eq0.00 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price80.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q80.65% Payout- Rel Volume0.15 Prev Close3.35
Sales Surprise-13.92% EPS Surprise-3.33% Sales Q/Q- Earnings- Avg Volume5.42K Price3.25
SMA2018.12% SMA5019.12% SMA2007.84% Trades Volume229 Change-2.99%
Date Action Analyst Rating Change Price Target Change
Oct-20-21Initiated Truist Buy $14
Sep-24-21Initiated Cantor Fitzgerald Overweight $7
Jun-03-19Initiated Credit Suisse Neutral
Jun-21-24 07:52AM
May-08-24 08:52AM
Apr-05-24 06:53AM
Mar-24-24 03:54PM
Dec-04-23 08:00AM
06:16PM Loading…
Nov-30-23 06:16PM
Aug-02-23 08:39PM
Jul-31-23 07:00AM
Jun-01-23 04:00PM
May-15-23 01:00PM
May-12-23 02:59PM
May-11-23 06:00PM
Apr-03-23 07:30AM
Mar-27-23 07:00AM
04:40PM Loading…
Mar-22-23 04:40PM
Nov-22-22 07:00AM
Nov-09-22 06:34AM
Oct-07-22 02:31PM
Oct-06-22 12:46PM
Aug-09-22 05:35PM
Aug-08-22 09:22AM
Jul-28-22 07:00AM
Jul-26-22 07:00AM
Jun-28-22 09:00AM
Jun-22-22 08:30AM
Jun-17-22 11:20AM
07:00AM Loading…
Jun-10-22 07:00AM
Jun-06-22 07:00AM
May-11-22 09:30AM
May-04-22 04:01PM
Feb-27-22 06:39AM
Feb-24-22 04:01PM
Feb-23-22 08:00AM
Feb-01-22 05:30AM
Jan-26-22 08:00AM
Dec-15-21 10:00AM
Nov-25-21 04:47AM
Nov-11-21 05:32PM
Nov-09-21 04:01PM
Nov-08-21 12:00PM
Oct-20-21 04:24PM
Oct-11-21 03:34AM
Oct-10-21 09:37AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-26-21 07:19AM
Aug-23-21 05:00PM
Jul-29-21 05:00PM
Jul-22-21 04:30PM
Jul-12-21 02:24AM
Jul-09-21 06:14AM
Jul-08-21 07:22PM
Jun-04-21 10:27AM
May-27-21 04:30PM
May-25-21 07:00AM
May-09-21 03:36AM
Apr-27-21 09:00AM
Apr-26-21 07:00AM
Apr-21-21 07:30AM
Apr-20-21 07:00AM
Mar-24-21 04:05PM
Mar-22-21 02:23AM
Mar-19-21 07:46AM
Mar-18-21 05:00PM
Feb-25-21 07:00AM
Jan-25-21 07:00AM
Jan-21-21 12:52AM
Jan-04-21 07:00AM
Dec-21-20 07:30AM
Dec-02-20 11:27PM
Nov-15-20 07:55AM
Nov-05-20 07:00AM
Oct-14-20 01:09PM
Oct-04-20 09:52AM
Sep-04-20 07:00AM
Aug-25-20 07:00AM
Aug-20-20 11:01AM
Aug-03-20 09:25AM
Jul-30-20 09:00AM
Jul-17-20 07:00AM
Jul-06-20 03:17PM
Jul-05-20 02:45PM
Jun-18-20 04:01PM
May-22-20 07:52AM
Apr-10-20 07:00AM
Mar-23-20 06:50AM
Jan-13-20 07:00AM
Jan-12-20 05:05PM
Dec-24-19 08:17AM
Dec-23-19 07:00AM
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCGUIRE TERRANCEDirectorAug 09 '23Sale3.408270Aug 11 04:25 PM